A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.
暂无分享,去创建一个
B. Storer | P. Westervelt | F. Appelbaum | C. Anasetti | K. Jerome | J. McCune | H. Frangoul | R. Abonour | P. Parker | P. Carpenter | L. Johnston | J. Lowder | H. Khoury | Paul Martin | P. Martin
[1] M. Boeckh,et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] D. Zahrieh,et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. , 2004, Blood.
[3] J. Ritz,et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.
[4] B. Andersson,et al. Tumor necrosis factor-blockade for the treatment of acute GVHD , 2004 .
[5] R. Krance,et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.
[6] B. van der Holt,et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.
[7] Paul Martin,et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. , 2002, Blood.
[8] M. Remberger,et al. Treatment of severe acute graft‐versus‐host disease with anti‐thymocyte globulin , 2001, Clinical transplantation.
[9] R. Vij,et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin , 2001, Bone Marrow Transplantation.
[10] S. Durrant,et al. Combination therapy with tacrolimus and anti‐thymocyte globulin for the treatment of steroid‐resistant acute graft‐versus‐host disease developing during cyclosporine prophylaxis , 2001, British journal of haematology.
[11] T. Gooley,et al. Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells1 , 2000, The Journal of Immunology.
[12] V. Emery,et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients , 2000, British journal of haematology.
[13] C. Currie,et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. , 2000, Journal of hematotherapy & stem cell research.
[14] E. Jaffe,et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.
[15] C. Anasetti,et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. , 1999, Transplantation.
[16] J Wagner,et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome , 1999, Bone Marrow Transplantation.
[17] S. Nantel,et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience , 1998 .
[18] C. Anasetti,et al. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. , 1997, Journal of immunology.
[19] H. Deeg,et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation , 1996 .
[20] M. Folstein,et al. Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.
[21] P. Ljungman,et al. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. , 1990, The Journal of infectious diseases.
[22] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[23] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.
[24] K. Cleary,et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. , 2000, Blood.